🇺🇸 FDA
Patent

US 9091696

Modulation of NR2F6 and methods and uses thereof

granted A61KA61K31/00A61K31/7088

Quick answer

US patent 9091696 (Modulation of NR2F6 and methods and uses thereof) held by Regen Biopharma, Inc. expires Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Regen Biopharma, Inc.
Grant date
Tue Jul 28 2015 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 23 2035 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K31/00, A61K31/7088